Rational Design of Highly Selective Spleen Tyrosine Kinase Inhibitors
Citations Over TimeTop 14% of 2012 papers
Abstract
A novel approach to design selective spleen tyrosine kinase (Syk) inhibitors is described. Inhibition of spleen tyrosine kinase has attracted much attention as a mechanism for the treatment of autoimmune diseases such as asthma, rheumatoid arthritis, and SLE. Fostamatinib, a Syk inhibitor that successfully completed phase II clinical trials, also exhibits some undesirable side effects. More selective Syk inhibitors could offer safer, alternative treatments. Through a systematic evaluation of the kinome, we identified Pro455 and Asn457 in the Syk ATP binding site as a rare combination among sequence aligned kinases and hypothesized that optimizing the interaction between them and a Syk inhibitor molecule would impart high selectivity for Syk over other kinases. We report the structure-guided identification of three series of selective spleen tyrosine kinase inhibitors that support our hypothesis and offer useful guidance to other researchers in the field.
Related Papers
- → Rigidification Dramatically Improves Inhibitor Selectivity for RAF Kinases(2019)21 cited
- → PKIS deep dive yields a chemical starting point for dark kinases and a cell active BRSK2 inhibitor(2020)18 cited
- → Identifying representative kinases for inhibitor evaluation via systematic analysis of compound-based target relationships(2020)7 cited
- → Structure Activity Relationship Studies around DB18, a Potent and Selective Inhibitor of CLK Kinases(2022)3 cited
- SHEDding light on the role of Pragmin pseudo-kinases in cancer.(2019)